+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05977803

Using CEST, IVIM, and ASL MRI Sequences to Diagnose Radionecrosis in Brain Metastases from Lung Cancer

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-03-31

60

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Brain metastases are common in cancer patients, especially those with lung cancer, which frequently spreads to the brain. This research aims to compare the diagnostic accuracy of a new MRI technique called the CEST sequence against the standard T2* infusion method with contrast injection. The goal is to improve how doctors distinguish between tumor growth and radionecrosis, a late side effect of radiotherapy occurring in brain metastases from lung cancer. Participants will undergo MRI scans that include three special sequences CEST, IVIM, and ASL. These sequences add about 10 minutes to the scanning time and do not require contrast injection for the CEST method. The study involves patients who have received radiotherapy for brain metastases and shows growth of these lesions on follow-up MRI. The study will evaluate diagnostic performance over 24 months, including blood flow mapping and tissue characterization. During the study, patients will have regular MRI scans using these sequences. Researchers will measure brain blood flow, tissue molecular content, and changes in white matter within and outside the radiation field. They will also monitor how well patients tolerate the MRI procedures. The main outcome is detecting hyperperfusion in brain metastases, with follow-up lasting up to two years to assess diagnostic accuracy and safety.

CONDITIONS

Brief Title

Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin

Research Team

A

Augustin Gaudemer, MD

M

Marie-Cécile Henry-Feugeas, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here